Long-term follow-up of cytogenetically normal CEBPA-mutated AML

Table 2 Cox Regression adjusted for additional markers

	OS			RFS
	HR	95% CI	p	HR	95% CI	p
biCEBPA versus moCEBPA (univariable analysis)	0.4	0.2-0.8	0.008	0.5	0.2-0.9	0.021
biCEBPA versus moCEBPA (adjusted for FLT3-ITD)	0.4	0.2-0.8	0.006	0.5	0.2-0.9	0.021
biCEBPA versus moCEBPA (adjusted for FLT3-TKD)	0.4	0.2-0.8	0.012	0.4	0.2-0.9	0.018
biCEBPA versus moCEBPA (adjusted for FLT3-ITD and FLT3-TKD)	0.4	0.2-0.8	0.006	0.4	0.2-0.8	0.012
biCEBPA versus moCEBPA (adjusted for FLT3-ITD, NPM1 mutations and interaction NPM1/FLT3-ITD)	0.2	0.1-0.5	<0.001	0.2	0.1-0.6	0.003
biCEBPA versus moCEBPA (adjusted for NPM1 mutations)	0.2	0.1-0.5	<0.001	0.2	0.1-0.6	0.002
biCEBPA versus moCEBPA (adjusted for PINA_OS or PINA_RFS (both without biCEBPA))	0.2	0.1-0.4	<0.001	0.2	0.1-0.6	0.001

Abbreviations: biCEBPA biallelic mutation in the CCAAT/enhancer-binding protein alpha, CI confidence interval, FLT3-ITD internal tandem duplication of the FLT3 gene, FLT3-TKD mutation in the tyrosine kinase domain of the FLT3 gene, HR hazard ratio, interaction NPM1/FLT3-ITD, NPM1 positive/FLT3-ITD positive versus NPM1 negative or FLT3-ITD negative, moCEBPA monoallelic mutation in the CCAAT/enhancer-binding protein alpha, NPM1, nucleophosmin gene, OS Overall survival, p p value, PINA_OS Prognostic Index for OS in cytogenetically normal AML [29], PINA_RFS Prognostic Index for RFS in cytogenetically normal AML [29], RFS Relapse-free survival.

ISSN: 1756-8722